openPR Logo
Press release

Dr. August Wolff GmbH & Co. KG Arzneimittel and Mercachem update on drug development collaborations

03-15-2012 06:33 AM CET | Science & Education

Press release from: Mercachem B.V.

Bielefeld, Germany & Nijmegen, the Netherlands – 14 March 2012. Dr. August Wolff GmbH & Co. KG Arzneimittel and Mercachem have reached important milestones in two drug development collaborations. In both projects in vivo proof of concept has been shown, moreover in one of them a preclinical candidate has been nominated. The development projects involve novel classes of molecules with potential use in dermatology.

‘We are of course very glad we have met the milestones defined for both projects. In particular, we are happy with the nomination of the preclinical candidate as a result of our efforts in lead optimization, since the agreed timeline for reaching this milestone was quite ambitious. The nominated compound is a molecule with three chiral centers for which we have managed to design a stereo-selective route with high yield.’ says Frank Leemhuis, Managing Director of Mercachem, ‘We believe that we have lived up to expectations for delivering high quality work and synthesizing complex novel molecules with drug-like properties.’.

Professor Christoph Abels, Medical Director, comments: ‘We are impressed by the problem-solving skills of Mercachem’s scientists. Both project teams are highly dedicated and committed to their project. Synthesis of all stereoisomers of one of our initial hits with three chiral centers and development of a highly stereoselective synthetic route for the most active stereoisomer in a short period of time clearly reflects Mercachem’s outstanding expertise in synthetic organic chemistry. This milestone facilitates a straight forward development. Toxicology can be initiated this year and a first clinical proof of concept following topical application will thus be very likely obtained in the second quarter of 2013’.

About Dr. August Wolff Arzneimittel
Dr. August Wolff GmbH & Co. KG Arzneimittel is a family owned research oriented company still located in Bielefeld, Germany. Dr. August Wolff GmbH & Co. KG Arzneimittel is selling medicinal products, medical devices and cosmetic products like Linola and Vagisan in several European countries. Since its establishment in 1905, Dr. August Wolff GmbH & Co. KG Arzneimittel has maintained strong focus in collaborations with universities to foster research and development in their search for novel products. More information about Dr. August Wolff GmbH & Co. KG Arzneimittel can be found on the company website (www.wolff-arzneimittel.de).

About Mercachem
Mercachem is a privately owned leading European contract research organization offering innovative chemistry, medicinal chemistry and early process research services to accelerate the drug discovery and development process in a flexible and cost-effective way. Mercachem was founded in 1997, occupies 3,500 m2 state-of-the-art research facilities in Nijmegen and employs approximately 100 chemists. Working for many pharmaceutical and biotech companies throughout the world, Mercachem is recognized for its high-quality products and services and its unprecedented problem solving capabilities. More information on Mercachem can be found on the company website (www.mercachem.com).

Dr. Wolff GmbH & Co. KG
Eva Gertz
Pressereferentin
Johanneswerkstraße 34 - 36
33611 Bielefeld
Germany
Tel. +49-(0)521-8808292 (-243)
Fax. +49-(0)521-8808254
Mob. +49-(0)171-2707535
Email: pr@dr-kurt-wolff.de

Mercachem B.V.
Jan Schultz
Director Business Development
Kerkenbos 2013
6564 BB Nijmegen
The Netherlands
Tel. +31-(0)24-3723300
Fax. +31-(0)24-3723305
Mob. +31-(0)6-14690769
Email: jan.schultz@mercachem.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Dr. August Wolff GmbH & Co. KG Arzneimittel and Mercachem update on drug development collaborations here

News-ID: 214354 • Views: 1402

More Releases from Mercachem B.V.

MERCACHEM ANNOUNCES APPOINTMENT OF DR. GERHARD MÜLLER AS SENIOR VICE PRESIDENT …
Nijmegen, the Netherlands - May 24, 2011. Mercachem is pleased to announce that Dr. Gerhard Müller has joined the management team of Mercachem as Senior Vice President Medicinal Chemistry thus supporting the strong growth of the medicinal chemistry services and projects. Gerhard will be responsible for expanding Mercachem’s activities in Medicinal Chemistry. Gerhard Müller joins Mercachem from Proteros fragments GmbH, where he had, for the last three years the position

More Releases for Wolff

Global Rotary Shearing Machine Market 2018-2025 Wolff Industries, Redson, Fintek …
Detailed market study on the "Global Rotary Shearing Machine Market" Research Report 2018-2025 By 9Dimen Research. It analyses the important factors of the Rotary Shearing Machine market based on present industry, Rotary Shearing Machine market demands, business strategies utilized by Rotary Shearing Machine market players and the future prospects from various angles in detail. Industry analysis is a market assessment tool used by business and analysts to understand the complexity of
Wolff Parkinson White Syndrome Market by Supply, Consumption, Cost, Profit analy …
Global Wolff Parkinson White Syndrome Market is accounted for USD 960 million in 2016 growing at a CAGR of 3.2% during the forecast period of 2017 to 2024. The upcoming market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024. Global Wolff Parkinson White Syndrome Market Industry 2018 Market Research Report focuses on price, sales, revenue and growth
Wolff Parkinson White Syndrome Market - Changing Supply And Demand Scenarios By …
The Global Wolff Parkinson White Syndrome Market is expected to reach US$ 1.2 billion by 2023, and the market is projected to grow at a CAGR of ~ 3.3 % during the forecast period 2017-2023. Wolff-Parkinson-White (WPW) syndrome is a rare congenital heart disorder involving irregularities in the electrical transmission system of the heart. In WPW syndrome, an abnormal alternate electrical pathway exists resulting in arrhythmias (abnormal heartbeat rhythms) and tachycardia
Wolff Parkinson White syndrome Market found Future opportunities of 2023
The Analysis presents the study of Global Wolff Parkinson White syndrome Market facilitating the regional and country wise analysis covering the strategic analysis of each market player and the market share they hold Wolff Parkinson White Syndrome Market Information: By Types (Type A, Type B) By Diagnosis (Electrocardiogram (ECG), Electrophysiological Testing, Others) By Treatment (Drugs (Anti-Arrhythmic, Beta-Blockers, Others), Cardioversion, Radiofrequency Catheter Ablation, Surgery, Artificial Pacemaker, Others) By End Users - Global
Wolff Parkinson White Syndrome Business Trends That Will Drive Success In 2023
The Global Wolff Parkinson White Syndrome Market is growing with the rapid pace; mainly due the burgeoning Healthcare Sector. According to a recent study report published by the Market Research Future, The global Wolff Parkinson White Syndrome Market is booming and expected to gain prominence over the forecast period. Wolff Parkinson White Syndrome Market Information: By Types (Type A, Type B) By Diagnosis (Electrocardiogram (ECG), Electrophysiological Testing, Others) By Treatment (Drugs
Wolff Parkinson White Syndrome Market Shows Highest Growth Potential of 3.3% by …
Market Research Future adds new report of “Wolff Parkinson White Syndrome Market Research Report- Global Forecast till 2023” it contains Company information, geographical data and Table of Content Competitive Analysis: Some of key players profiled in the report are • AngioDynamics • Medtronic • Boston Scientific Corporation • St. Jude Medical, LLC • Abbott • GlaxoSmithKline LLC • Teva Pharmaceutical Industries • Sanofi S.A. • Novartis International AG Get a Sample Report @ https://www.marketresearchfuture.com/sample_request/4224 Market Segments: The global Wolff Parkinson White syndrome market has been segmented on the basis of types, diagnosis,